生物
异柠檬酸脱氢酶
转录组
染色质
癌症研究
遗传异质性
IDH1
基因沉默
遗传学
基因
突变
基因表达
表型
生物化学
酶
作者
Ramya Raviram,Anugraha Raman,Sebastian Preißl,Jianfang Ning,Shaoping Wu,Tomoyuki Koga,Kai Zhang,Cameron Walter Brennan,Chenxu Zhu,Jens Luebeck,Kinsey Van Deynze,Jee Yun Han,Xiaomeng Hou,Zhen Ye,Anna K. Mischel,Yang Eric Li,Rongxin Fang,Tomas Babak,Joshua W. Mugford,Claudia Z. Han
标识
DOI:10.1073/pnas.2210991120
摘要
In 2021, the World Health Organization reclassified glioblastoma, the most common form of adult brain cancer, into isocitrate dehydrogenase (IDH)-wild-type glioblastomas and grade IV IDH mutant (G4 IDHm) astrocytomas. For both tumor types, intratumoral heterogeneity is a key contributor to therapeutic failure. To better define this heterogeneity, genome-wide chromatin accessibility and transcription profiles of clinical samples of glioblastomas and G4 IDHm astrocytomas were analyzed at single-cell resolution. These profiles afforded resolution of intratumoral genetic heterogeneity, including delineation of cell-to-cell variations in distinct cell states, focal gene amplifications, as well as extrachromosomal circular DNAs. Despite differences in IDH mutation status and significant intratumoral heterogeneity, the profiled tumor cells shared a common chromatin structure defined by open regions enriched for nuclear factor 1 transcription factors (NFIA and NFIB). Silencing of NFIA or NFIB suppressed in vitro and in vivo growths of patient-derived glioblastomas and G4 IDHm astrocytoma models. These findings suggest that despite distinct genotypes and cell states, glioblastoma/G4 astrocytoma cells share dependency on core transcriptional programs, yielding an attractive platform for addressing therapeutic challenges associated with intratumoral heterogeneity.
科研通智能强力驱动
Strongly Powered by AbleSci AI